Neurocrine Biosciences, Inc. (NBIX) concluded trading on Wednesday at a closing price of $123.76, with 4.83 million shares of worth about $597.44 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -8.09% during that period and on August 28, 2024 the price saw a loss of about -18.87%. Currently the company’s common shares owned by public are about 100.98M shares, out of which, 98.73M shares are available for trading.
Stock saw a price change of -17.98% in past 5 days and over the past one month there was a price change of -12.34%. Year-to-date (YTD), NBIX shares are showing a performance of -6.07% which increased to 15.79% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $103.63 but also hit the highest price of $157.98 during that period. The average intraday trading volume for Neurocrine Biosciences, Inc. shares is 791.40K. The stock is currently trading -16.82% below its 20-day simple moving average (SMA20), while that difference is down -14.22% for SMA50 and it goes to -8.65% lower than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) currently have 100.98M outstanding shares and institutions hold larger chunk of about 92.97% of that.
The stock has a current market capitalization of $12.50B and its 3Y-monthly beta is at 0.38. PE ratio of stock for trailing 12 months is 37.39, while it has posted earnings per share of $3.31 in the same period. Its PEG reads 1.14 and has Quick Ratio of 4.08 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NBIX, volatility over the week remained 2.72% while standing at 2.95% over the month.
Stock’s fiscal year EPS is expected to rise by 99.30% while it is estimated to increase by 39.60% in next year. EPS is likely to shrink at an annualized rate of 32.80% for next 5-years, compared to annual growth of 62.04% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wells Fargo on April 24, 2024 offering an Overweight rating for the stock and assigned a target price range of between $140 and $170 to it. Coverage by Citigroup stated Neurocrine Biosciences, Inc. (NBIX) stock as a Neutral in their note to investors on December 13, 2023, suggesting a price target of $127 for the stock. On December 12, 2023, Deutsche Bank Initiated their recommendations, while on October 24, 2023, Cantor Fitzgerald Resumed their ratings for the stock with a price target of $140. Stock get a Neutral rating from Mizuho on August 21, 2023.
